諾誠健華-B(09969.HK):3754.8萬股超額配股權獲行使 穩定價格期結束
格隆匯4月16日丨諾誠健華-B(09969.HK)公告,聯席全球協調人於2020年4月15日悉數行使招股章程所述超額配股權,涉及合共3754.8萬股股份,約佔根據全球發售初步可供認購的發售股份的15%,以補足國際發售的超額分配。
公司將以每股股份8.95港元配發及發行超額配發股份。超額配發股份將用於促使向Sunland Bio Med Ltd及Sunny View Holdings Limited歸還曾用於補足國際發售中的超額分配的3754.8萬股借入股份。聯交所上市委員會已同意及批准超額配發股份上市及買賣。超額配發股份預期將於2020年4月22日上午九時正於聯交所主板開始上市及買賣。
此外,全球發售的穩定價格期間已於2020年4月15日(即遞交香港公開發售申請的截止日期起計第30日)結束。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.